RLMD - Relmada Therapeutics beefs up leadership team; updates on REL-1017 program

Relmada Therapeutics ([[RLMD]] -1.4%) has expanded its leadership team with appointments of Dr. Paolo Manfredi, M.D., as acting Chief Scientific Officer and Marco Pappagallo, M.D., as acting Chief Medical Officer ((CMO)).Dr. Pappagallo most recently served as CMO at CerSci Therapeutics.Dr. Manfredi has been the co-founder of Medeor and served as Scientific Director and co-inventor of REL-1017.The company will commence, its first pivotal Phase III trial of REL-1017 for the adjunctive treatment of major depressive disorder in the 4Q. In the 3Q, the company expects to begin its human abuse potential studies of REL-1017.Other anticipated milestones for REL-1017 in 2021 include:1H21 – Start of second Phase III adjunctive MDD trial;1H21 – Start of Phase II monotherapy MDD trial;2Q21 – Results of human abuse potential studies;4Q21 – Results of Phase II monotherapy MDD trial and,1H22 – Results of Phase III adjunctive MDD trials.

For further details see:

Relmada Therapeutics beefs up leadership team; updates on REL-1017 program